Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 59

1.

Radiation-induced esophagitis exacerbated by everolimus.

Miura Y, Suyama K, Shimomura A, Miyakawa J, Kobayashi H, Uki A, Okaneya T, Takano T.

Case Rep Oncol. 2013 Jun 15;6(2):320-4. doi: 10.1159/000353309.

3.
4.

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.

Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP.

Cancer. 2009 Jun 1;115(11):2438-46. doi: 10.1002/cncr.24280.

5.

Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.

Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ.

Clin Cancer Res. 2008 Feb 1;14(3):892-900. doi: 10.1158/1078-0432.CCR-07-0955.

6.

Reversible posterior leukoencephalopathy syndrome during sunitinib therapy for metastatic renal cell carcinoma.

Hadj JO, Braven RD, Tillier C, Schrijver HM, Verheul HM, VAN DER Vliet HJ.

Oncol Lett. 2012 Jun;3(6):1293-1296.

7.
8.

Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.

Chan HY, Grossman AB, Bukowski RM.

Adv Ther. 2010 Aug;27(8):495-511. doi: 10.1007/s12325-010-0045-2. Review.

PMID:
20623346
9.

Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.

Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-89-S12-95.

PMID:
9331129
10.

Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.

Mauceri HJ, Sutton HG, Darga TE, Kocherginsky M, Kochanski J, Weichselbaum RR, Vokes EE.

Oncol Rep. 2012 May;27(5):1625-9. doi: 10.3892/or.2012.1666.

PMID:
22294050
11.

Pulsed reduced dose-rate radiotherapy as re-irradiation for brain metastasis in a patient with lung squamous-celled carcinoma.

Li GH, Liu Y, Tang JL, Zhang D, Zhou P, Yang DQ, Ma CK.

Jpn J Clin Oncol. 2012 Sep;42(9):856-60. doi: 10.1093/jjco/hys091.

12.

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.

Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O'Brien S, Andreeff M, Giles FJ.

Clin Cancer Res. 2006 Sep 1;12(17):5165-73.

13.

Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.

Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K.

Jpn J Clin Oncol. 1994 Oct;24(5):275-81.

PMID:
7967106
14.

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ.

Eur J Cancer. 2011 Jun;47(9):1287-98. doi: 10.1016/j.ejca.2011.02.014. Review.

PMID:
21481584
15.
16.
17.

Hepatitis B reactivation related to everolimus.

Sezgin Göksu S, Bilal S, Coşkun HŞ.

World J Hepatol. 2013 Jan 27;5(1):43-5. doi: 10.4254/wjh.v5.i1.43.

18.

[Advanced renal cell carcinoma showing a different response to two types of interferon-alpha].

Horiguchi A, Uchida A.

Nihon Hinyokika Gakkai Zasshi. 2004 Jan;95(1):50-3. Japanese.

19.

Everolimus induced Pneumonitis.

Badar Q, Masood N, Abbasi AN.

Gulf J Oncolog. 2015 May;1(18):18-24.

PMID:
26003100
20.

Acute secondary effects in the esophagus in patients undergoing radiotherapy for carcinoma of the lung.

Mascarenhas F, Silvestre ME, Sá da Costa M, Grima N, Campos C, Chaves P.

Am J Clin Oncol. 1989 Feb;12(1):34-40.

PMID:
2536215
Items per page

Supplemental Content

Support Center